BioNTech SE (BNTX) Gross Margin (2018 - 2026)
BioNTech SE (BNTX) posted Gross Margin of 63.27% for Q4 2025, down 29.89% sequentially from 90.24% in Q3 2025, and down 3672.0% YoY from 1.77% in Q4 2024.
Powered by 
Analysis
BioNTech SE (BNTX) Gross Margin (2018 - 2026) Analysis & Trends
BioNTech SE has reported Gross Margin for 8 years, with the latest figure at 63.27% in Q4 2025.
- Quarterly Gross Margin fell 3672.0% year-over-year to 63.27% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 77.83% (down 2216.0% YoY) and the FY2025 annual result came in at 77.64%, down 269.0% from the prior year.
- Gross Margin retreated to 63.27% in Q4 2025 per BNTX's latest filing, from 90.24% in the prior quarter.
- Over five years, Gross Margin peaked at 100.0% in Q3 2021 and troughed at 2.86% in Q2 2023.
- A 5-year average of 77.12% and a median of 82.64% in 2023 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2023 and 2024: Gross Margin tumbled 7322 bps in 2023, then surged 5067 bps in 2024.
- Over 5 years, Gross Margin stood at 89.46% in 2021, then gained by 7 bps to 95.71% in 2022, then slipped by 8 bps to 87.89% in 2023, then gained by 14 bps to 99.99% in 2024, then slumped by 37 bps to 63.27% in 2025.
- According to Business Quant data, Gross Margin over the past three periods registered 63.27%, 90.24%, and 70.71% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | BioNTech SE | 25.06 Bn | 11.41 Bn | 10.00 Mn | 8.14% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.14% |
| Mar 31, 2026 | 39.54% |
| Dec 31, 2025 | 63.27% |
| Sep 30, 2025 | 90.24% |
| Jun 30, 2025 | 70.71% |
| Mar 31, 2025 | 54.16% |
| Dec 31, 2024 | 79.54% |
| Sep 30, 2024 | 85.63% |
| Jun 30, 2024 | 53.54% |
| Mar 31, 2024 | 68.50% |
| Dec 31, 2023 | 87.89% |
| Sep 30, 2023 | 81.93% |
| Jun 30, 2023 | 2.86% |
| Mar 31, 2023 | 92.48% |
| Dec 31, 2022 | 95.71% |
| Sep 30, 2022 | 78.25% |
| Jun 30, 2022 | 76.08% |
| Mar 31, 2022 | 79.70% |
| Dec 31, 2021 | 89.46% |
| Sep 30, 2021 | 99.57% |